Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 37, Issue 1 (Jan 1999)

Issues

Determination of Free Apolipoprotein(a) in Serum by Immunoassay and Its Significance for Risk Assessment in Patients with Coronary Artery Disease

Wolfgang Herrmann / Sabine Quast / Kai Wolter / Hartmut Eger / Stefan T. Kießig / Harry Hahmann / Jörg Kreuter / Ewald Molinari
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.1999.003

Abstract

This paper describes a new enzyme-linked ligand sorbent assay (ELLSA) to quantify free apolipoprotein(a) (apo(a)). The new test immobilizes free apo(a) utilizing a specific peptide that carries the amino acid sequence of a non-covalent apo(a) binding site on apoB3375–3405 (ligand-peptide). The ligand-peptide coupled to Sepharose was used in affinity chromatography to separate free apo(a) from whole serum. Isolated free apo(a) consisted of full length apo(a) and smaller apo(a). Additionally, free apo(a) levels determined by ELLSA as well as by electroimmunodiffusion correlated moderately well. Significantly increased serum concentrations of free apo(a) were found in coronary artery disease. The mean value of free apo(a) was three times higher in patients than in controls while the lipoprotein(a) (Lpla)) concentration was doubled. Utilizing receiver operating characteristic diagrams, it was shown that the free apo(a)-ELLSA had a better diagnostic test performance in atherosclerotic risk assessment than the Lp(a)-test: specificity free apo(a)-ELLSA 0.77, Lp(a)-test 0.81 [with (a:a)-enzyme immunoassay (EIA)] to 0.83 [with (a:B)-EIA]; sensitivity free apo(a)-ELLSA 0.57, Lp(a)-test 0.36 to 0.40. In conclusion, the new free apo(a)-ELLSA allows for the specific quantification of free apo(a). This provides an interesting indicator for atherosclerotic risk assessment.

About the article

Published Online: 2005-06-01

Published in Print: 1999-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.1999.003.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Angelo M Scanu, Celina Edelstein, and Olga Klezovitch
Trends in Cardiovascular Medicine, 1999, Volume 9, Number 7, Page 196
[2]
Mahendra Narain Mishra, Ravi Kalra, and Shalesh Rohatgi
Sao Paulo Medical Journal, 2013, Volume 131, Number 6, Page 384
[3]
K. M. Kostner, W. Marz, and G. M. Kostner
European Heart Journal, 2013, Volume 34, Number 42, Page 3268
[4]
Audrey O.T. Lau, Alias J. Smith, Mark T. Brown, and Patricia J. Johnson
Molecular and Biochemical Parasitology, 2006, Volume 150, Number 1, Page 56
[5]
Jürgen Geisel, Benno Hennen, Ulrich Hübner, Jean-Pierre Knapp, and Wolfgang Herrmann
Clinical Chemistry and Laboratory Medicine, 2003, Volume 41, Number 11
[6]
Jean-Pierre Knapp and Wolfgang Herrmann
Clinical Chemistry and Laboratory Medicine (CCLM), 2004, Volume 42, Number 9

Comments (0)

Please log in or register to comment.
Log in